- Home
- PIM vs CNTB Comparison
PIM vs CNTB Comparison
Compare PIM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PIM | CNTB |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 128.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PIM | CNTB |
|---|---|---|
| Price | $3.34 | $2.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 57.5K | ★ 93.6K |
| Earning Date | 01-01-0001 | 03-31-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24,739.01 |
| P/E Ratio | $63.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.90 | $0.51 |
| 52 Week High | $3.28 | $3.28 |
Technical Indicators
Market Signals| Indicator | PIM | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 60.38 |
| Support Level | $3.28 | $2.23 |
| Resistance Level | $3.32 | $2.70 |
| Average True Range (ATR) | 0.03 | 0.25 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 72.22 | 100.00 |
Price Performance
Historical ComparisonAbout PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.